New Developments in Clinical Pharmacy and Clinical Pharmacology

June 17, 2017
Düsseldorf, Germany
8:00-9:00  Registration/Coffee  
Haus der Universität, Schadowplatz 14

9:00-9:15  Welcome  
Hartmut Derendorf  
University of Florida  
Cornelia Désirée Sonntag  
Galenus Foundation

9:15  Update from the University of Florida College of Pharmacy  
Julie Johnson  
University of Florida

9:30  Minitables in clinical practice – multiple new options for individual drug dosing  
Jörg Breitkreutz  
University of Düsseldorf

9:45  How Pharmacists Can Mitigate Drug-Drug Interaction Risks  
Larry Lesko  
University of Florida

10:00  LENA – a European project for better drugs for children with heart failure  
Stephanie Läer  
University of Düsseldorf

10:15  Development and implementation of an EHR-based real-time prediction model for drug-induced hypoglycemia in hospitalized patients  
Almut Winterstein  
University of Florida

10:30  Modeling & Simulation Updates  
Sem Lampotang  
University of Florida
10:45  Break

11:00  Clinical Translation of a Sigma Receptor Ligand: From Design to Human Trials  
       Chris McCurdy  
       University of Florida

11:15  Life Beyond Science  
       Ravi Chandran  
       Signature Pharmaceuticals, Dallas

11:30  Model-based safety analysis of oncology drugs using post-marketing real world data  
       Yusuke Tanigawara  
       Keio University, Tokyo

11:45  Once Weekly Dulaglutide 1.5 mg Restores Insulin Secretion in Response to Intravenous Glucose Infusion  
       Amparo de la Pena  
       Lilly, Indianapolis

12:00  Exosomes: New kid on the block for drug delivery  
       Thomas Schmittgen  
       University of Florida

12:15  Presentation of GlobalGator Award

Previous Awardees:

2015   Paul Doering
2013   William Riffee
2011   Emil Pop
2009   Willy Roth
2007   Marcus Brewster
<table>
<thead>
<tr>
<th>Time</th>
<th>Session Description</th>
<th>Speaker</th>
<th>Institution/Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>12:30</td>
<td>Lunch</td>
<td></td>
<td></td>
</tr>
<tr>
<td>13:30</td>
<td><em>Pharmacogenomics implemented into daily work</em></td>
<td><em>Julie Johnson</em></td>
<td>University of Florida</td>
</tr>
<tr>
<td>13:45</td>
<td><em>The Value of Pharmacometrics in Development and Clinical Use of Anti-infective Therapies.</em></td>
<td><em>Sebastian Wicha</em></td>
<td>Uppsala University, Sweden</td>
</tr>
<tr>
<td>14:00</td>
<td><em>Quantitative clinical pharmacology – what’s in it for me?</em></td>
<td><em>Stephan Schmidt</em></td>
<td>University of Florida</td>
</tr>
<tr>
<td>14:15</td>
<td><em>Vitamin D and the Free Hormone Hypothesis</em></td>
<td><em>John Lima</em></td>
<td>Nemours Hospital, Jacksonville</td>
</tr>
<tr>
<td>14:30</td>
<td><em>Identification of Biomarkers for Early Detection of Drug-Induced Nephrotoxicity using a Translational Physiologically Based Pharmacokinetic (PBPK) DDI Model</em></td>
<td><em>Mirjam Trame</em></td>
<td>University of Florida</td>
</tr>
<tr>
<td>14:45</td>
<td><em>Therapeutic drug monitoring of anti-MRSA drugs: recent updates in Japan</em></td>
<td><em>Kazuro Ikawa</em></td>
<td>Hiroshima University, Japan</td>
</tr>
<tr>
<td>15:00</td>
<td>Break</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
15:30  Update on UF Clinical Pharmacy Master’s Program  
Karen Whalen  
University of Florida

15:45  Home Medication versus Prescription  
Olaf Rose  
University of Bonn; Elephantenapotheke, Steinfurt

16:00  Developing models for Clinical Pharmacy and Pharmacy education in Korea  
Han-Jun Chae  
Chonbuk National University Korea

16:15  The role of pharmacists in a multidisciplinary team: best practices from Germany and the U.S.  
Andreas Niclas Förster/Jochen Pfeifer  
Adler-Apotheke, Velbert

16:30  Back in practice: A overview of my personal journey of retraining to take on practice in a new area after many years of not practicing  
Randell Doty  
University of Florida

16:45  Medication Safety—Quick-Check in hospitalized patients  
Sonja Mayer  
Johannes-Apotheke, Gröbenzell

17:00  Direct-to-Consumer Prescription Drug Advertising: Good Thing or Bad?  
Paul Doering  
University of Florida
**19:00**  
**Reception and Group Photo**  
**Gator Fest and Dinner**  
Rheinterassen, Rheingoldsaal  
Joseph-Beuys-Ufer 33

**Late Night**  
**Nightcap**  
Quartier Boheme  
Ratingerstr. 25

<table>
<thead>
<tr>
<th>Year</th>
<th>Symposium</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>2015</td>
<td>10th</td>
<td>Utrecht, The Netherlands</td>
</tr>
<tr>
<td>2013</td>
<td>9th</td>
<td>Garmisch-Partenkirchen, Germany</td>
</tr>
<tr>
<td>2011</td>
<td>8th</td>
<td>Graz, Austria</td>
</tr>
<tr>
<td>2009</td>
<td>7th</td>
<td>Stresa, Italy</td>
</tr>
<tr>
<td>2007</td>
<td>6th</td>
<td>Munich, Germany</td>
</tr>
<tr>
<td>2005</td>
<td>5th</td>
<td>Leuven, Belgium</td>
</tr>
<tr>
<td>2003</td>
<td>4th</td>
<td>Vienna, Austria</td>
</tr>
<tr>
<td>2001</td>
<td>3rd</td>
<td>Dresden, Germany</td>
</tr>
<tr>
<td>1999</td>
<td>2nd</td>
<td>Reims, France</td>
</tr>
<tr>
<td>1997</td>
<td>1st</td>
<td>Münster, Germany</td>
</tr>
</tbody>
</table>
Hartmut Derendorf, Ph.d., is Distinguished Professor, V. Ravi Chandran Professor of Pharmaceutical Sciences and Chairman of the Department of Pharmaceutics at the University of Florida College of Pharmacy in Gainesville. He currently also serves as the 18th University of Florida Distinguished Alumni Professor. Prof. Derendorf has published over 450 scientific publications and nine textbooks in English and German. He is Editor or Associate Editor of five Journals such as the Journal of Clinical Pharmacology. Prof. Derendorf has served as President of the American College of Clinical Pharmacology (ACCP) and President of the International Society of Antiinfective Pharmacology (ISAP). He was awarded the Distinguished Research Award, the Mentorship Award and the Nathaniel T. Kvit Distinguished Service Award of ACCP, the Research Achievement Award in Clinical Science of the American Association of Pharmaceutical Sciences (AAPS), the Leadership Award of the International Society of Pharmacometrics (ISOP) and the Volwiler Award of the American Association of Colleges of Pharmacy (AACP).

Julie A. Johnson, Pharm.D., is Dean of the University of Florida College of Pharmacy and Distinguished Professor of Pharmacy and Medicine. She is also Director of the UF Health Personalized Medicine Program. She received her B.S. in Pharmacy from the Ohio State University and her Pharm.D. from the University of Texas at Austin and the UT Health Science Center at San Antonio. She completed a post-doctoral fellowship in cardiovascular pharmacology/ pharmacokinetics at Ohio State. Dr. Johnson is an internationally-recognized leader in cardiovascular pharmacogenomics and genomic medicine, with over 250 peer reviewed publications and nearly $40M in research funding as principal investigator. In 2015 and 2016 she was included as a Thomson Reuters Highly Cited Scientist in Pharmacology and Toxicology, indicating she is in the top 1% of scientists in the field globally. Dr. Johnson has had leadership roles in the American College of Clinical Pharmacy (ACCP), the American Heart Association (AHA), and the American Society of Clinical Pharmacology and Therapeutics (ASCPT), for which she completed her term as President in 2017. She is an elected fellow of the ACCP, the AHA and the American College of Clinical Pharmacology. Dr. Johnson was elected to the National Academy of Medicine (formerly Institute of Medicine) in 2014 and has received numerous other awards including the Leon I Goldberg Young Investigator Award from the ASCPT (2004), Paul Dawson Biotechnology Research Award, American Association of Colleges of Pharmacy (AACP) (2007), AACP Volwiler Research Achievement Award (2016), among others.
Jörg Breitkreutz, born in Marl in 1966, studied pharmacy at the Westfälische Wilhelms-Universität Münster from 1987 to 1991. In 1992, he received his license as a pharmacist and also earned his diploma at the Ernst-Moritz-Arndt-Universität Greifswald. From 1992 to 1996, he promoted the use of molecular modeling and experimental studies on the molecular structure of polyethylene glycols and their interactions with water and phenol at the Institute for Pharmaceutical Technology and Biopharmaceutics in Münster. In 1996 and 1997 he was the head of product coordination and deputy manufacturing manager at Thiemann Arzneimittel GmbH in Waltrop. From 1997 onwards he researched again at the University of Münster, where he habilitated in 2004 on the topic "development of child-friendly medicines". In the same year he accepted a call to the Heinrich Heine University of Düsseldorf (HHU) as a C3 professor for Pharmaceutical Technology and Biopharmaceutics. His work includes the development, production and testing of new pediatric drugs and innovative drugs for rare diseases, known as orphan drugs. He also deals with process-analytical technologies that make pharmaceutical production processes safer, more energy-efficient and resource-conserving.

Larry Lesko, Ph.D., is Professor of Pharmaceutics and Director of the Center for Pharmacometrics and Systems Pharmacology in the University of Florida, College of Pharmacy at Lake Nona (Orlando). Dr. Lesko co-authored numerous Guidance for Industry including “Clinical Pharmacogenomics: Premarketing Evaluation in Early Clinical Trials” and “Pharmacogenomics Data Submissions”. He also started a Division of Pharmacometrics that is responsible for quantitative analysis of dose-response and PK-PD relationships to support drug labels and NDA approvals, and the development of drug-disease models to support clinical trial simulations. Dr. Lesko has published more than 200 peer-reviewed manuscripts and is a frequent invited national and international speaker. In 2011, he received the Gary Neil Prize for Innovation in Drug Development from the American Society of Clinical Pharmacology and Therapeutics (ASCPT). Dr. Lesko also was honored with the Rawls-Palmer Progress in Medicine award from ASCPT, the Coriell Scientific Leadership Award for Personalized Medicine, the University of North Carolina Institute for Pharmacogenomics and Individualized Therapy Award for Clinical Service, and the Nathanial B. Kwit Distinguished Service Award for Clinical Pharmacology from the American College of Clinical Pharmacology.
Stephanie Läer, MD, Ph.D., is Professor of Clinical Pharmacy and Pharmacotherapy at the University of Düsseldorf with a background of a pharmacist (University of Braunschweig) and a physician (University of Göttingen). She was trained as a Pharmacologist and Toxicologist, Clinical Pharmacologist at the University Hospital of Hamburg where she also received her habilitation. In 2003 she received a Heisenberg fellowship from the German Research Foundation for research and collaboration with the University of Tennessee in Memphis, U.S.A. In 2004 she established the Institute of Clinical Pharmacy and Pharmacotherapy at the University of Düsseldorf. Her institute is at the interface between Pharmacy and Medicine. One research area is the optimization of drug therapy for children. Since 2011 she serves as General Secretary for the European Society of Developmental Perinatal and Paediatric Pharmacology (ESDPPP) http://www.esdppp.org/site/2015-congress-belgrade/. The ESDPPP aims for improving research and access to children’s medicines worldwide and also works closely with IUPHAR and WHO. Prof. Läer and her research team performs clinical studies with German community pharmacists to improve pharmacotherapy for patients (DIADEMA http://www.diabetes-online.de/a/diadema, AWATAR) using innovative simulation training tools (PHARMADHERE). They also coordinate European paediatric studies with the aim to develop better drugs for children (LENA GA No 602295; www.lena-med.eu/). Prof. Läer’s research has gained several awards. Last awards in 2017 were in the context of the DIADEMA project (Award of the LAV-Petrick-Foundation; Trainee Award Community Pharmacy from Apothekerverband Nordrhein).

Almut Winterstein, Ph.D., received her pharmacy degree from Friedrich Wilhelm University in Bonn, Germany and her PhD in Pharmacoepidemiology from the Charité Humboldt University in Berlin, Germany. She holds the position of Professor and Chair in the Department of Pharmaceutical Outcomes and Policy at the College of Pharmacy, and an affiliate appointment in the Department of Epidemiology at the Colleges of Medicine and Public Health and Health Professions, both at the University of Florida. In 2017, she was named the Dr. Robert and Barbara Crisafi Chair in recognition of her research on evaluating drug safety and effectiveness in real-world populations and on devising ways to improve medication use. Since joining the UF College of Pharmacy in 2000, Winterstein has served as principal investigator on more than 25 extramurally funded grants and contracts and published more than 300 manuscripts and conference abstracts. Her research interests have centered on the post-marketing evaluation of drugs in pediatrics and perinatal care, infectious disease and psychiatry and the evaluation and improvement of quality surrounding medication use using real-world data. As internationally recognized expert in drug safety, she chairs the Food and Drug Administration’s Drug Safety and Risk Management Advisory Committee. In 2013, Dr. Winterstein was inducted as a fellow of the International Society of Pharmacoepidemiology. Before she became department chair in 2016, Dr. Winterstein served as graduate program director in her department, which included responsibility for a MS program for the FDA. She has chaired a total of 19 PhD committees and has served as member on another 14 in her department, Epidemiology, and Statistics.
Samsun Lampotang, Ph.D., is a Professor of Anesthesiology and Director of the Center for Simulation, Safety and Advanced Learning Technology at the University of Florida in Gainesville, Florida. He received his Ph.D. in mechanical engineering at the University of Florida, College of Engineering. His research interest is in simulation in healthcare, healthcare equipment, and promotion of patient safety through enhancement of learning and improved equipment design. Dr. Lampotang is part of the UF team that conceived the patented technology behind the Human Patient Simulator. The team’s simulation research shifted to what has become transparent reality simulation on the web in the form of the Virtual Anesthesia Machine (VAM) simulation. The simulation portfolio has become diversified to include airway devices, perioperative hemostasis, CVVH/dialysis, pharmacokinetics, and physics.

Christopher McCurdy, Ph.D., is a broadly trained medicinal chemist, behavioral pharmacologist and pharmacist whose research focuses on the design, synthesis and development of drugs to treat pain and drug abuse. For over 20 years, much of his research has focused on opioid, Neuropeptide FF and sigma receptor ligand/probe design, synthesis, pharmacological evaluation and development. He has been successful in discovering unique and selective tools for sigma receptors, NPFF receptors and opioid receptors. He is an internationally recognized expert on Kratom (Mitragyna speciosa), that is under investigation for opioid withdrawal syndrome. A significant portion of his career has been dedicated to the development of novel sigma receptor ligands, in collaboration with a variety of interdisciplinary groups, to generate and optimize selective ligands which could serve as critical experimental tools, and more recently, as potential medication development leads to attenuate the effects of cocaine, methamphetamine and pain. Most notably, he has developed a PET/MR imaging diagnostic agent for visualizing the origins of chronic, neuropathic pain by interacting with sigma receptors at the site of nerve damage. First-in-human studies are currently underway in a Phase 0 trial. In addition to his discovery chemistry roles, McCurdy serves as the director of the UF Translational Drug Development Core. Dr. McCurdy is currently President-Elect of the American Association of Pharmaceutical Scientists (AAPS) and also serves as the Co-Chair of the Special Interest Group on Drug Design and Discovery (DDD) of the International Pharmaceutical Federation (FIP).
Ravi Chandran, Ph.D., is a distinguished alumni of the University of Florida, USA where he graduated with a PhD in pharmaceutical sciences in 1986. Since then, as an independent scientist and business leader, he has been engaged in pharmaceutical manufacturing, research and development of new drug molecules, hitech drug manufacturing and distribution in the USA, and has more than 25 patents for excess of 9000 new molecules in various countries including USA, Japan, Australia and others. With his breakthrough research in Anti-platelet drugs, Dr. Chandran demonstrated that to develop a new drug, it is not necessary to start with thousands of molecules. Instead, by combining ideas from a multidisciplinary approach, few drugs can be zeroed in on at a very early stage and carry them to final regulatory approval. Dr. Chandran is an experienced pilot, enjoys flying airplanes and helicopters as his hobby.

Yusuke Tanigawara, Ph.D., is Professor of Clinical Pharmacokinetics and Pharmacodynamics, Keio University School of Medicine, Tokyo, Japan. He is an Adjunct Faculty of University of Florida, College of Pharmacy. He received his Ph. D. in pharmaceutical sciences from Kyoto University in 1983. His research interests include pharmacokinetics, pharmaco-dynamics and optimal dosing algorithms for personalized medicine. He has been studying clinical pharmacokinetics and pharmacodynamics mainly for oncology drugs and antimicrobial agents. His modeling and simulation studies on population pharmacokinetics and pharmacodynamics were applied to new drug development as well as rational use for patient care. Recently, he also investigates pharmacogenomics as a factor causing individual variation in drug response, and multi-omics biomarkers by means of proteomics and metabolomics. He is distinguished as one of the "ISI Highly Cited Researchers."
**Amparo de la Peña, Ph.D.,** received a BS in Chemistry and a Pharmaceutical Chemist degree from the University of the Republic, Uruguay; and a doctorate in Pharmaceutics from the University of Florida, Gainesville under Dr. Derendorf’s guidance. She joined Lilly as a PK/PD scientist in the year 2000 and has contributed to the development of drugs in several therapeutic areas, including anti-infectives, diabetes and neuroscience. Amparo has authored more than 30 publications in US and international peer-reviewed journals. She currently works at Chorus; a division of Eli Lilly which evaluates drugs from early phase to proof of concept, as a Research Advisor for PK/PD. In her free time, she writes non-scientific prose and mothers her very energetic boys.

**Thomas Schmittgen, Ph.D.,** is a professor in the Department of Pharmaceutics at the University of Florida in Gainesville. He holds both undergraduate (Pharmacy) and graduate degrees (Pharmaceutics) from Ohio State University. He was a National Research Service Award (NIH) postdoctoral fellow at the University of Southern California from 1992-1995. He served on the faculty at Washington State University College of Pharmacy before returning to Ohio State in 2002. He joined the University of Florida in 2015. Dr. Schmittgen’s research focuses on noncoding RNAs and cancer with emphasis on the use of microRNAs as therapeutic or diagnostic agents. A paper he co-authored in 2001 describing the relative method of gene quantification has been cited over 65,000 times and was recently ranked by the international journal *Nature* as the 21st most cited scientific article of all time. Dr. Schmittgen has been continuously funded by federal agencies (NIH, DOD) for the past 20 years. His lab was the first to establish a link between altered microRNA expression in pancreatic cancer. Recently Dr. Schmittgen has focused his attention on the development of exosomes/microvesicles as targeted drug delivery systems for the treatment of cancer. Dr. Schmittgen is a member of the American Association for Cancer Research, American Association for the Advancement of Science and is a Fellow of the American Association of Pharmaceutical Scientists.
Sebastian Wicha, PhD., studied pharmacy in Freiburg, Germany. After a research internship at the University of Florida in 2010, and receiving his licensure as pharmacist in 2011, he started his PhD in Clinical Pharmacy at the Freie Universität Berlin, Germany under the supervision of Prof. Charlotte Kloft, which he completed in 2015. Thereafter, he pursued a post-doctoral fellowship at the Pharmacometrics Research Group at Uppsala University, before he was appointed as a Junior Professor of Clinical Pharmacy at the University of Hamburg, Germany in 2017. In his research, he focuses on describing biological systems with mathematical models with the aim to improve drug therapy with projects focusing on anti-infectives and oncology. He is the lead developer of the TDMx Software, a set of applications to foster model-supported therapeutic drug monitoring. Dr. Wicha received several awards for his research, e.g. the Scheele Award for his PhD thesis from the German Association of Pharmaceutical Sciences, 2016. Dr. Wicha is an active member of several scientific societies (German Association of Pharmaceutical Sciences, PK/PD study group of the European Society of Clinical Microbiology and Infectious Diseases) and is appointed as Secretary at the International Society of Anti-Infective Pharmacology (ISAP).

Stephan Schmidt, Ph.D., is an Assistant Professor & Associate Director of the Center for Pharmacometrics and Systems Pharmacology as well as Associate Chair of the Department of Pharmaceutics in Lake Nona (Orlando). He received his B.S. in Pharmaceutical Sciences from the Friedrich-Alexander University in Erlangen, Germany, his PhD from the University of Florida with Hartmut Derendorf before completing a 3-year post-doc at Leiden University with Meindert Danhof. His primary research focuses on translational science, specifically on the application of quantitative data analysis as a process to address questions and support decisions in drug development and regulatory science. Dr. Schmidt works collaboratively with colleagues in the pharmaceutical industry and the FDA in a range of therapeutic areas including cardiovascular-metabolic (diabetes, osteoporosis) and antimicrobial chemotherapy. He has extensive expertise with populations of all ages ranging from pediatrics to geriatrics. Performance indicators for Dr. Schmidt's research include over 40 peer-reviewed publications, frequently with co-authors from industry or FDA sponsors, the training of 13 post-doctoral research associates, 5 Ph.D. students and 4 international scholars. His trainees most often fill hiring needs in the industry and FDA with the next-generation of job-ready scientists. Dr. Schmidt is an expert scientist in physiologically based PK (PBPK) modeling, exposure-response modeling and model-based analysis of clinical pharmacology data.
John Lima, PharmD., is Principal Research Scientist Emeritus at Nemours Children’s Health System and is co-PI of the Nemours Airway Clinical Research Centers (ACRC) and a co-investigator in NHLBI’s AsthmaNet. Dr. Lima received his BS degree from the Massachusetts College of Pharmacy in 1967, and his PharmD degree from the University of Michigan in 1977. He completed fellowship training in Clinical Pharmacokinetics at the SUNY at Buffalo. In 1979, Dr. Lima was an Assistant Professor of Pharmacy in the College of Pharmacy, at the Ohio State University, and an Associate Professor in 1984. In 1992, he was Professor of Clinical Pharmacy and Pharmaceutical Sciences at the University of Tennessee, in Memphis, TN. Dr Lima completed a sabbatical in the Department of Pharmacology, University of Pennsylvania in 1991, where he studied receptor expression and regulation. Dr. Lima chairs the Genetics Working Group of the American Lung Association ACRC and holds membership in the American Thoracic Society. Dr. Lima’s research focus is in the area of Pharmacogenomics of asthma drugs, proton pump inhibitors and vitamin D and is active in implementing pharmacogenomics testing of drugs in children. He is an active member of IGNITE through the Personalized Medicine Program at the University of Florida. Currently Dr. Lima has funding from the NIH, American Lung Association, Thrasher Foundation and Nemours Biomedical Research. He has published more than 180 full papers peer-reviewed journals.

Mirjam Trame, PharmD, Ph.D., joined the University of Florida as an Assistant Professor at the Center for Pharmacometrics and Systems Pharmacology in Lake Nona (Orlando) in May 2014. She holds an Adjunct Faculty appointment at the Translational Research Institute for Metabolism and Diabetes at Florida Hospital, Orlando. She received her B.S. from the Westfälische-Wilhelms Universität in Münster, Germany in 2006 and her license to practice as a pharmacist in Germany in 2007. She earned her Pharm.D. degree from the University of Florida in 2010 and her Ph.D. in Clinical Pharmacology and Pharmacokinetic-Pharmacodynamic (PK/PD) modeling from the Westfälische-Wilhelms Universität in Münster, Germany in 2011. In addition, she was awarded for with the ACoP 2013 Trainee Award to predict potential QT liability based on Phase I dECG data. Her research interest include the application of quantitative analysis tools (pharmacometrics and systems pharmacology) to address clinically relevant research questions in the area of diabetes, obesity, antithrombotic therapy, neurodegenerative diseases, rare diseases, pediatrics, cardiovascular safety, cystic fibrosis, and translational research.
Kazuro Ikawa, Ph.D., is the Associate Professor, Department of Clinical Pharmacotherapy, Hiroshima University and also an Adjunct Faculty, College of Pharmacy, University of Florida. He started his career as a clinical pharmacist at Oita Medical University Hospital (Apr 1994-Aug 1999), worked as a reviewer for drug approval at Ministry of Health, Labor and Welfare (Japanese FDA) (Sep 1999-Jun 2003), and then transferred to Hiroshima University. His research focuses on clinical pharmacokinetics and pharmacodynamics at target sites especially for antimicrobial agents. He studied more about site-specific PK-PD of antibiotics at Dr. Derendorf’s laboratory, University of Florida (Jul-Sep 2010). He is a Fellow of American College of Clinical Pharmacology, and his work with more than 100 English articles is recognized by several awards from societies such as Japanese Society of Clinical Pharmacology and Therapeutics, and Japanese Society of Pharmaceutical Health Care and Sciences.

Karen Whalen, Pharm.D., BCPS, CDE, FAPhA is Assistant Dean for Clinical Education and Clinical Professor in the Department of Pharmacotherapy and Translational Research at the University of Florida College of Pharmacy. She received her Doctor of Pharmacy degree with highest honors from the University of Florida. She then completed a Pharmacy Practice Residency at Moses Cone Hospital followed by a Primary Care Residency at James A. Haley Veterans’ Hospital. In 2008, Dr. Whalen joined the faculty at the University of Florida, College of Pharmacy. She now serves as Director of the MS in Pharmacy with concentration in Medication Therapy Management degree program, as well as Director of the MS in Pharmacy with concentration in Clinical Pharmacy. Dr. Whalen is a Board Certified Pharmacotherapy Specialist and a Certified Diabetes Educator. She has practiced ambulatory care pharmacy in a variety of settings including an academic family medicine center, a nurse-managed rural health clinic, and a Veterans’ Affairs Healthcare System. She is active in local, state and national pharmacy organizations, and is a past president of the Florida Pharmacy Association and a Fellow of the American Pharmacists Association.
Olaf Rose, PharmD studied Pharmacy in Münster, Germany and worked as a research fellow for Bayer-Yakuhin in Japan. He graduated with his Pharm.D. at the UF in 2009 and was distinguished with the 'professional leadership award' of the UF. Rose is initiator of the WestGem-Study, an European-Union funded project to show the efficacy of Medication Therapy Management regarding quality of therapy, quality of life and costs, integrating several Universities, professions, study centers and specialized pharmacists. He is involved in several further studies and research activities in this field. Rose is editor of manifold Pharmacotherapy literature and promoting Clinical Pharmacy with lectures, articles and a monthly series about patient-oriented pharmacy together with Hartmut Derendorf in Germany. Rose is owner of 3 community pharmacies and lives in Münster, Germany.

Han-Jung Chae, PharmD PhD is a pharmacologist at the Department of Pharmacology at Chonbuk National University Medical School and a director for Center for laboratory Animal Research at Chonbuk National University General Hospital, Jeonju, Korea. Chonbuk National University is a national research university founded in 1947, located in Jeonju, Republic of Korea. As the flagship national university for the Jeollabuk-do province (Chonbuk means Jeonbuk for Jeollabuk-do), Chonbuk National University has been ranked 501–550th in the world by QS Top Universities Ranking in 2016. The University has 17 colleges (including Faculty of Public Policy, Jimmy Carter School of International Studies) and 14 graduate schools (one general, nine specialized and four professional graduate schools). The main campus provides approximately 32,000 enrolled students, and 2,000 faculty and staff members with educational, research and support facilities. She had a Pharm D degree from WPPD program in 2008. She was trained as a post-doc researcher at the Samford Burnham Institute at La Jolla, CA between 2001 and 2003. From 2002, She works as a professor at Chonbuk University Medical School. She has been also actively involved in Clinical Trial design and management from 2004. Also in the pharmacology field, She shows outstanding achievement. More importantly, She is leading a team of establishment of a new Pharmacy School at Chonbuk National University. Through her experience about clinical pharmacology and pharmacy, she has a plan to start new pharmacy school at Korea.
Andreas Niclas Förster, PharmD
is Clinical Assistant Professor for Professional Education at the College of Pharmacy, University of Minnesota and a registered pharmacist in Germany. He currently works as head pharmacist of the Adler Apotheke in Velbert, Germany after 3 years in the Research and Development Department of Bayer HealthCare in Germany. He is a lecturer for continued education of pharmacists in Germany and reviews pharmacotherapy for the Doctor's Association (KVNo) in his state. He studied pharmacy in Germany, France and the United States, where he received an accomplishment award for research conducted at the Department of Pharmaceutics of the University of Florida.

Jochen "Josh" Pfeifer, Ph.D., PharmD, has studied pharmacy at the University of Düsseldorf and earned his PharmD degree at the University of Florida in the WPPD program in 2006. He is the owner of the Adler Apotheke in Velbert, Germany (in the 4th generation). For his work on clinical pharmacy and medication management he was awarded two German pharmacy awards. His major specialties are interprofessional cooperation with physicians as well as international exchange programs with pharmacy students and pharmacists from around the world. Dr Pfeifer is Clinical Assistant Professor at the College of Pharmacy of the University of Florida.
**Sonja Mayer, Ph.D.,** studied pharmacy at the University of Regensburg and received her Doctor degree at the University of Munich, Germany. From 1998 until 2012 she worked for the Bavarian Chamber of Pharmacists in Munich, Germany. Her responsibility includes Bavarian Drug Information Centers, further education, Pharmaceutical Care and Bavarian Academy of Clinical Pharmacy. Dr. Sonja Mayer is author of many publications and oral / poster presentations at international meetings, she is editor of a book on drug information. She is specialised in drug information and geriatric pharmacy. She was a co-organizer of the biennial international 6th Global Gator Meeting in Munich (2007). Since 2012 she works for Johannes-Apotheke KV in Gröbenzell. She established medication therapy management in a German community setting. The research of the team was honored with awards like the WIPIG award best cooperation physician and pharmacist 2014 and Dr. Hellmuth Häussermann award 2016.

**Randell Doty, PharmD.,** received a Doctor of Pharmacy degree from the University of Tennessee in 1988 and completed a general clinical residency at the Veterans Administration Medical Center in Memphis Tennessee in 1989. He accepted an appointment in the Department of Pharmacy Practice at the University of Florida in 1989 and served as Associate Director of the Computer Applications in Pharmacy Center until it closed in 1991. Dr. Doty is a Clinical Associate Professor in the Department of Pharmacotherapy and Translational Research. He served for more than 20 years as director of Experiential Programs at the University of Florida College of Pharmacy and currently co-coordinates the Pathophysiology and Patient Assessment course sequence in the first year. He also teaches in the skills lab, instructs students in their immunization training and practices in the UF Health adult Emergency Department.
Paul Doering MS, is an Emeritus Distinguished Service Professor in the Department of Pharmacotherapy and Translational Research, the university’s highest honor awarded to a faculty member. He was the first professor in the College of Pharmacy to be recognized in this way at the University of Florida, College of Pharmacy. He is also Co-director of the statewide Drug Information and Pharmacy Resource Center. He is a past-president of his local pharmacy association. Doering has been recognized four times as Teacher of the Year. In March, 1990, he was awarded Fellowship status in the APhA’s Academy of Pharmacy Practice and Management. In 1993, he received one of two Teaching Incentive Awards given to UF College of Pharmacy faculty.
Organizers

Prof. Hartmut Derendorf
University of Florida

Prof. Jörg Breitkreutz
University of Düsseldorf

Prof. Stephanie Läer
University of Düsseldorf

The generous support of

University of Florida, College of Pharmacy
Boehringer Ingelheim
Drug & Biotechnology Development
Elsevier
Galenus Foundation
Merck KGaA
PKPDyne, Inc.
Ravi Chandran, Ph.D.
Roche
Sanofi

is gratefully acknowledged.

Global Gator Club e.V.

Please send your updated contact information to
Bridgette Armas
barmas@cop.ufl.edu